GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Indian TB Diagnostic Technology Receives Praise at World Health Assembly

NextEdge Admin

14 Jun 2024

2 min 57 sec

The Truenat platform, developed by Molbio in Goa, India, has garnered significant attention and praise for its pivotal role in the fight against tuberculosis (TB) worldwide. Launched in 2017, Truenat represents a breakthrough in molecular diagnostics, offering rapid and accurate testing for pulmonary, extrapulmonary, and rifampicin-resistant TB.

Operating on real-time quantitative micro-PCR technology, Truenat is a portable, battery-operated device that can be deployed in various settings, including laboratories, health centers, and field operations. Its efficiency is underscored by its ability to deliver test results within an hour, enabling prompt diagnosis and treatment initiation. Notably, Truenat's versatility extends beyond TB, with the capacity to test for over 40 different diseases.

During the 77th World Health Assembly in Geneva, the Global Fund, in collaboration with the World Health Organization (WHO), commended India's efforts in TB eradication, particularly highlighting innovative initiatives such as the widespread adoption of Truenat machines and handheld X-ray devices. These technologies, designed for challenging environments, have demonstrated their effectiveness in enhancing case detection and improving healthcare delivery.

Sriram Natarajan, CEO of Molbio, expressed gratitude for the recognition received at the global level, citing Truenat's growing presence with approximately 10,000 installations worldwide. In India, Truenat has been integrated into the National TB Elimination Programme, with over 7,000 primary health centers and community health centers utilizing the platform, alongside approximately 1,500 private laboratories.

At the Assembly, Union Health Secretary Apurva Chandra emphasized the importance of continued support from organizations like The Global Fund to strengthen public health systems and bolster TB control efforts. Given the staggering toll of TB, which claims the lives of an estimated 480,000 Indians annually, early diagnosis and treatment remain paramount. With over 10 million new cases reported globally each year, India bears a significant burden, accounting for 27% of total cases.